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CXCL12 expression promotes esophageal
squamous cell carcinoma proliferation and
worsens the prognosis
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Abstract
Background: The chemokine CXCL12 and its corresponding receptor CXCR4 are key players in the development of
several cancers. Therefore, we hypothesized that there is a functional causality between CXCL12 expression and
tumor progression in patients with esophageal squamous cell carcinoma (ESCC).
Methods: We performed an immunohistochemical analysis in 79 consecutive patients with ESCC. We performed in
vitro and in vivo cell proliferation assays using ESCC cell lines and a newly established transfectant stably
overexpressing CXCL12.
Results: Immunohistochemistry revealed positive CXCR4 and CXCL12 expression in 48 (61 %) and 62 (78 %)
patients, respectively. Additionally, the expression levels did not significantly correlate with any clinicopathological
factors. The MIB-1 proliferation index was markedly higher in ESCC with a positive expression of CXCR4 or CXCL12.
Positive CXCL12 expression was significantly correlated with lower recurrence-free survival (RFS, p = 0.02). Cox’s
hazard models revealed CXCL12 expression as an independent predictive factor for recurrence. In vitro, CXCL12
exposure or overexpression enhanced ESCC proliferation; and AMD3100, a specific inhibitor of CXCR4, equally
decreased proliferation irrespective of CXCL12 exposure or overexpression. In the mouse model, AMD3100
significantly decreased ESCC tumor size (p = 0.03).
Conclusions: CXCL12 stimulates ESCC proliferation, and its expression levels are related to lower RFS in patients
with ESCC. Our findings indicate that positive CXCL12 expression may be a useful marker for predicting the
outcome in patients with ESCC and is a potentially new therapeutic target for ESCC.
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Background
Esophageal cancer is one of the most malignant solid tu-
mors with a 5-year survival rate of <19 % [1]. Squamous
cell carcinoma (SCC) is one of the two most common
histologic types of esophageal cancer. The three main
treatment options available for esophageal SCC (ESCC)
are surgery, chemotherapy and radiotherapy. Studies
evaluating the efficacy of combining these three modal-
ities showed only a limited improvement in the progno-
sis [2–5].
A potential breakthrough may arise if the mechanism
of ESCC proliferation can be clarified. Several studies re-
ported that chemokines with lymphocyte chemoattract-
ant capacities and chemokine receptors promote the
progression of malignant tumors [6–10]. CXCR4, the re-
ceptor for chemokine CXCL12, was defined as the co-
receptor used by the T-lymphotropic human immuno-
deficiency virus (HIV)-type 1 strains for cellular entry
[11]. AMD3100, a bicyclam in which two cyclam rings
are tethered by an aromatic bridge, selectively blocks
CXCR4 and inhibits HIV replication [12]. Specifically, it
blocks the interaction between gp120 (viral envelope
glycoprotein) and CXCR4. The correlation was reported
between the inhibitory effects of AMD3100 on HIV-1
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replication, and CXCL12-mediated signal transduction
(CXCL12-induced Ca2+ flux). AMD3100 is a highly spe-
cific CXCR4 antagonist inhibiting CXCL12-mediated
Ca2+ flux in a number of cells expressing CXCR4, but
has no inhibitory effect on chemokine induced signalling
from other chemokine receptors [11]. AMD3100 inter-
acts with CXCR4 extracellularly and mechanistically pre-
vents the binding of CXCL12 to CXCR4 and thus
downstream signalling of CXCR4. [11, 13]. AMD3100 is
not toxic to host cells at concentrations up to 500 mM
and the CXCL12/CXCR4 blockade efficiently decreases
cancer cell proliferation [11, 14].
Although the relationship between CXCL12/CXCR4
expression levels and cell behaviour was described in a
variety of malignant tumors [14–18], few have assessed
this relationship for esophageal cancer. In this study, we
analysed the relationship between CXCL12/CXCR4 ex-
pression and tumor proliferation in patients with ESCC.
We further investigated the correlation between
CXCL12/CXCR4 expression levels and clinicopathologi-
cal features. Our in vitro and in vivo results show that
CXCL12 promotes ESCC proliferation.
Methods
Patient selection
Patients were enrolled in the study if they met the fol-
lowing inclusion criteria: (1) pathologically confirmed
ESCC after radical esophagectomy at Keio University
Hospital between 1997 and 2007; (2) no history of radio-
therapy or chemotherapy prior to surgery; (3) R0 resec-
tion and (4) complete follow-up information. Each
patient enrolled in this study signed an informed con-
sent form.
This study was approved by the Institutional Review
Board at Keio University School of Medicine.
Immunohistochemistry
Esophageal specimen tissues were obtained from surgical
resection. Tumor samples were fixed with 10 % formalin
in phosphate-buffered saline, embedded in paraffin and
sectioned into 4-μm slices. The slides were deparaffi-
nised in xylene and dehydrated in a graded ethanol
series. The sections were incubated in Target Retrieval
Solution PH6.0 (Dako, Glostrup, Denmark) for 10 min
at 121 °C. The endogenous peroxidase activity was
blocked by immersing the slides in 0.5 % periodic acid
for 10 min at room temperature. After washing with
water, the sections were treated with 4 % BlockAce (DS
Pharma Biomedical, Osaka, Japan) for 30 min to block
nonspecific reactions at 37 °C. The blocked sections
were incubated with the primary diluted antibody at
4 °C overnight. The primary antibodies were diluted
as follows: CXCL12 (MAB350, 1:200; R&D Systems,
Minneapolis, USA) and CXCR4 (ab2074, 1:500;
Abcam Inc., Cambridge, UK) were diluted in Can Get
Signal Immunostain Solution A (Toyobo, Osaka,
Japan), and Ki67 (SP6, 1:200; Thermo Fisher Scien-
tific, Waltham, USA) was diluted in 4 % BlockAce.
The sections were rinsed with Tris-buffered saline
(TBS) followed by an incubation with ENVISION
(Dako) for 30 min at room temperature. After the
TBS washes, the sections were stained with a DAB
kit (Dako), counterstained with hematoxylin and
mounted. For each staining protocol, a negative con-
trol without the primary antibody was included. We
evaluated CXCL12, CXCR4 and Ki67 expression on
slides for viable ESCC cells belonging to the most in-
vasive tumor lesion. We observed four different vision
fields under high magnification (×400). To assess the
immunoreactivity of CXCL12 and CXCR4, the sec-
tions were scored in terms of their proportion (score
0: −10 %, 1: 10–40 %, 2: 40–70 %, and 3: >70 %) and
intensity (score 0: none, 1: weak, and 2: strong). The
immunoreactive score (IRS) was defined as the prod-
uct of the proportion and intensity scores. For the
final statistical analysis, an IRS value of 0 was ranked
as the negative expression and IRS values of 1–6 were
ranked as positive expression. The MIB-1 proliferation
index was calculated as the percentage of Ki67 posi-
tive cells. Two investigators (UY and TH) blinded to
the clinicopathological factors assessed the
immunohistochemistry.
Animals
All animal experiments were executed according to In-
stitutional Guidelines on Animal Experimentation at
Keio University and were approved by The Keio Univer-
sity Institutional Animal Care and Use Committee. Fe-
male BALB/cA nude mice were purchased from
Oriental Yeast Co., Ltd (Tokyo, Japan). The mice were
maintained under specific pathogen-free conditions at
Keio University Experimental Animal Center and fed
sterile food and water. In each experiment, 10 mice aged
6 weeks were used. They were allocated to two groups
and the weight prior to the intervention did not signifi-
cantly differ among the groups (data not shown).
Esophageal cell lines
We used eight established ESCC cell lines (TE-1, 4, 5, 6,
8, 9, 10, and 11) provided by Dr. Nishihira (Tohoku Uni-
versity, Miyagi, Japan). The identity of each cell line was
confirmed by short tandem repeat analysis [10].
RNA extraction and quantitative real-time RT-PCR
Total RNA from each ESCC cell line was extracted and
analysed by quantitative real-time RT-PCR using the
7300 Real Time PCR system (Applied BioSystems, Carls-
bad, CA), TaqMan Gene Expression Master Mix
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(Applied BioSystems) and ready-to-use CXCR4/CXCL12
primers (Assay ID: Hs00607978_m1 for CXCR4 and
Hs00171022_m1 for CXCL12; Applied BioSystems).
Glyceraldehyde-3-phosphate dehydrogenase was used as
an internal control. We used human lymphocytes from a
healthy donor (UY) as a positive control and distilled
water without the template as a negative control. The
relative quantity of CXCR4 and CXCL12 mRNA in
ESCC cell lines was calculated using the ΔΔCt method.
The expression levels of TE1 and TE4 were defined as 1
for the evaluation of CXCR4 and CXCL12 expression
levels, respectively. All assays were performed in
triplicate.
Establishment of a stable CXCL12-overexpressing cell line
CXCL12 mRNA was extracted from a healthy volun-
teer’s (UY) lymphocytes. The full-length open reading
frame was amplified and inserted into the plasmid vector
pFLAG-CMV-4 (Sigma Aldrich, St. Louis, MO). The
plasmids were transfected to TE4 cells using Lipofecta-
mine 2000 Reagent (Invitrogen, Carlsbad, CA). When
CXCL12 overexpression was confirmed by quantitative
real-time RT-PCR, the stable transfectant was denoted
TE4CXCL12+.
In vitro proliferation assay
We examined the effect of CXCL12 on ESCC prolifera-
tion using water soluble tetrazolium (WST) salt. TE4
and TE4CXCL12+ (1 × 104) were seeded in a 96-well plate
(day 0) after overnight serum starvation. The following
day, cells were exposed to different concentrations of
CXCL12 (25 nM, R&D Systems) and/or AMD3100. Cell
viability was measured using Cell Counting Kit-8
(Dojindo, Kumamoto, Japan) per the manufacturer’s in-
struction after 72 h. The assays were performed in tripli-
cate. We defined the ‘proliferation index’ as the
absorbance ratio of day 3 over day 0.
In vivo proliferation assay
Ten 6-week-old nude mice were injected with
TE4CXCL12+ (1 × 106) on day 0. Two dorsal skinfold
chambers implanted on the back of each mouse. The
following day, the animals were assigned to two different
groups. The dorsal skinfold chamber was opened, and a
mini-osmotic pump (Alzet, 200 μL, pumping rate:
1.0 μL/h) filled with AMD3100 (35 μg/μL) was im-
planted into five mice; a mini-osmotic pump filled with
0.1 % bovine serum albumin was implanted in five con-
trol mice. The pumps were exchanged under general an-
aesthesia every week. All operations were performed by
the same surgeon. All animals underwent measurements
of the tumor size on days 3, 7, 10 and 14 to assess
whether the blockade of CXCL12-CXCR4 binding in-
hibits the tumor progression in vivo. One investigator
(UY) who was blinded to the treatment measured the
tumor size.
Statistical analyses
Mann-Whitney U test, Pearson’s χ2 test or Fisher’s exact
probability test was used to assess the correlation be-
tween CXCL12/CXCR4 expression levels and clinico-
pathological characteristics. The Kaplan-Meier and log-
rank tests were used for the survival analysis. Cox pro-
portional hazard models were used for multivariate ana-
lysis of variables predicting postoperative survival. In the
mouse model and in vitro proliferation assay, the
Mann-Whitney U test was used to calculate the stat-
istical significance of the tumor size or the absorb-
ance, respectively. All statistical procedures were
performed using SPSS v18.0 software (SPSS, Tokyo,
Japan). A p value of less than 0.05 was considered to
be statistically significant.
Results
CXCL12/CXCR4 expression and clinicopathological
characteristics
The patient characteristics are presented in Table 1. The
median age of the enrolled patients was 59 years (range:
44–79), and the male/female ratio was 71/8. Representa-
tive images of immunohistochemistry are shown in Fig. 1.
Forty-eight patients (61 %) were positive for CXCR4 and
62 (78 %) for CXCL12 expression (Table 2). The group
with a positive CXCL12 expression was more likely to
also have a positive CXCR4 expression compared with
the group with negative CXCL12 expression; 41 pa-
tients (52 %) were positive for both CXCR4 and
CXCL12. We found that patients with a positive
expression of CXCL12 tended to have a higher lymph
node recurrence rate than other patients (Table 3, p
= 0.08). No other significant correlation between the
expression of CXCR4 or CXCL12 and other clinico-
pathological factors was found.
The mean follow-up time was 68 months. During
follow-up, 34 (43 %) of 79 patients experienced tumor
recurrence. Figures 2 and 3 show the Kaplan–Meier
curves of recurrence-free survival (RFS) and overall sur-
vival according to the expression of CXCL12 or CXCR4.
The patients with a positive CXCL12 expression exhib-
ited a significantly lower RFS (p = 0.02). CXCR4 expres-
sion, however, had no correlation with survival rate.
Figure 4 shows the comparison of the survival among
the four groups (including CXCL12+ and CXCR4+,
CXCL12+ and CXCR4-, CXCL12- and CXCR4-, and
CXCL12- and CXCR4+), which showed no significant
diffence among them. Patients with CXCL12-positive
ESCC tended to have a poor prognosis regardless of the
positive or negative expression of CXCR4.
Uchi et al. BMC Cancer  (2016) 16:514 Page 3 of 11
Univariate and multivariate analyses were performed
to determine the predictors of subsequent tumor recur-
rence. We evaluated six variables for survival prognosis
by univariate analysis (Table 4). We detected positive
CXCL12 expression, lymph node metastasis, lymphatic
invasion and vessel invasion as predictive markers of
RFS. We performed the multivariate analysis for these
four prognostic factors. In conclusion, a positive
CXCL12 expression is an independent risk factor for
subsequent tumor recurrence, showing the highest haz-
ard ratio compared with other pathological features.
We demonstrated subgroup multivariate analysis by
dividing the population into two groups by existence of
adjuvant therapy. Positive CXCL12 expression was an
independent risk factor for postoperative recurrence in
the group without adjuvant therapy (p = 0.03, hazard ra-
tio = 5.19, n = 62). However, no clinicopathological
factors, including positive CXCL12 expression were de-
tected as a significant risk factor for recurrence in the
group with adjuvant therapy. This was likely due to an
insufficient number of patients (n = 17).
The MIB-1 proliferation index was markedly
higher in ESCC with a positive expression of CXCR4
or CXCL12, especially with positive CXCR4 expres-
sion (CXCR4 21.8 vs 7.6 %, p = 0.03; CXCL12 17.9 vs
7.6 %, p = 0.20; all percentage values are median). As
shown in Table 5, ESCC with positive expression of
both CXCR4 and CXCL12 exhibited a significantly
higher MIB-1 index than the other three groups
(24.1 vs 7.5 %, p = 0.02). These results suggest that
CXCL12 expression increases the proliferation of
ESCC through signal transduction after binding to
the CXCR4, which in turn leads to an earlier recur-
rence after surgery. We subsequently surveyed the
relationship between CXCL12 expression and ESCC
proliferation in vitro and in vivo.
CXCR4 and CXCL12 mRNA expression in TE cell lines
CXCR4 and CXCL12 mRNA expression in ESCC cell
lines were assessed by quantitative real-time RT-
PCR. All ESCC cell lines express CXCR4 at different
levels (data not shown). Similarly, the CXCL12
mRNA expression level varies among cell lines, with
the highest expression level seen in TE8 cells
(Fig. 5a) and other cell lines showing a very low ex-
pression level or no expression at all. We selected
the TE4 cell line for its low expression level of
CXCL12 to establish transfectants overexpressing
CXCL12. The original TE4 cell line was tumorigenic
in nude mice. We established six different
Table 1 Patient characteristics
Patients
(n = 79)
Age (median, range) 59 (44–79)
Gender (male/female) 71/8
Histological grade (1/2/3) 16/57/6
Depth of tumor invasion (Tis/T1/T2/T3) 10/35/7/27
Lymph node metastases (+) 46 (58 %)
Lymphatic invasion (+) 58 (73 %)
Vessel invasion (+) 35 (44 %)
Adjuvant therapy (none/chemotherapy
/chemoradiotherapy)
62/16/1
Initial recurrence after surgery (none/lymph
node/distant organ/both lymph node and distant organ)
45/14/10/10
Fig. 1 Representative images of immunohistochemical staining of CXCL12 and CXCR4
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TE4CXCL12+ cell lines that overexpressed CXCL12 by
gene transfer and used one for further investigation.
This line was transplantable to mice and showed a
410-fold increase in CXCL12 expression compared
with the untreated TE4 line (Fig. 5b).
In vitro proliferation assay
Figure 6 presents the proliferation index of TE4 in
the WST cell proliferation assay with or without ex-
posure to CXCL12 and in the presence or absence
of AMD3100. When exposed to CXCL12, the TE4
cells showed a significantly higher proliferation index
than control (p = 0.002). However, when exposed to
AMD3100, the TE4 cells showed a significantly
lower proliferation index than untreated TE4 cells
(p = 0.001). CXCL12 was not able to increase the
proliferation rate of TE4 cells exposed to AMD3100.
Figure 7 shows the proliferation index of TE4 and
TE4CXCL12+ in the presence or absence of AMD3100.
Table 2 Relationship between CXCR4 and CXCL12 expression
CXCR4 (−) CXCR4 (+) Total
CXCL12 (−) 10 (13 %) 7 (9 %) 17 (22 %)
CXCL12 (+) 21 (27 %) 41 (52 %) 62 (78 %)
Total 31 (39 %) 48 (61 %) 79
p = 0.09
Table 3 Relationship between expression of CXCL12/CXCR4 and clinicopathological factors
All patients (n = 79) (%)
CXCR4(+) CXCR4(−) p CXCL12(+) CXCL12(−) p
n = 48 (61) n = 31 (39) n = 62 (78) n = 17 (22)
Age, median (range) 58.5 (44–79) 61 (44–74) 0.84c 59 (44–79) 57 (50–70) 0.84c
Gender
Male 44 27 0.71a 54 17 0.19a
Female 4 4 8 0
Histological grade
1 11 5 0.69b 12 4 0.90b
2 34 23 45 12
3 3 3 5 1
Pathological T
Tis 5 5 0.63b 8 2 0.39b
T1 24 11 28 7
T2 4 3 7 0
T3 15 12 19 8
Pathological N
Positive 28 18 0.98b 36 10 0.96b
Negative 20 13 26 7
Lymphatic invasion
Absent 13 8 0.90b 17 4 1.00a
Present 35 23 45 13
Vessel invasion
Absent 27 17 0.90b 36 8 0.42b
Present 21 14 26 9
Recurrence of lymph node metastasis
Positive 13 11 0.43b 22 2 0.08a
Negative 35 20 40 15
Recurrence of distant organ metastasis
Positive 13 7 0.65b 17 3 0.54a
Negative 35 24 45 14
Recurrence of lymph node metastasis or distant organ metastasis means that the initial recurrence region after ESCC resection was lymph node or distant organ
aFisher’s exact probability test
bPearson’s χ-square test
cMann-Whitney U test
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The TE4CXCL12+ cells showed a significantly higher
proliferation index than the original TE4 cells (p =
0.03). Adding AMD3100 significantly decreased the
proliferation of both TE4 and TE4CXCL12+ cells to
the same extent (both p = 0.001). The decrease
shown in Figs. 6 and 7 was observed not only on
day 3, but the tendency was already present on day
1 and 2 (data not shown).
These results indicate that CXCL12 expressed by TE4
or TE4CXCL12+ is secreted, binds to its specific receptor,
CXCR4, on the cell membrane and stimulates cellular
proliferation via signal transduction. AMD3100 inhibits
the binding between CXCL12 and CXCR4 and subse-
quently decreases cell proliferation.
In vivo proliferation assay
Figure 8 shows the different tumor sizes following a
subcutaneous injection of TE4CXCL12+ in the back of
nude mice combined or not with a continuous subcuta-
neous infusion of AMD3100. Mice injected with
TE4CXCL12+ and infused with AMD3100 had smaller tu-
mors than the controls at all time points. On day 14, the
tumor size was significantly decreased by the AMD3100
infusion (p = 0.03). This result indicates that AMD3100
Months from surgery Months from surgery
Recurrence free survival Overall survival 
CXCL12 negative
n=17
CXCL12 positive
n=62
p = 0.23 p = 0.02
CXCL12 negative
n=17
CXCL12 positive
n=62
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Fig. 2 Survival curves of patients after esophagectomy with positive or negative CXCL12 expression. The patients with positive CXCL12
expression exhibit a significantly lower recurrence-free survival (p = 0.02)
CXCR4 negative
          n=31
CXCR4 positive
          n=48
p = 0.77 p = 0.97
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Recurrence free survivalOverall survival 
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          n=31
CXCR4 positive
          n=48
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Fig. 3 Survival curves of patients after esophagectomy with positive or negative CXCR4 expression. Positive expression of CXCR4 in ESCC is not
correlated with survival rate
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decreases ESCC proliferation by inhibiting the CXCL12/
CXCR4 signalling pathway artificially enhanced by
TE4CXCL12. No adverse events were observed during the
assay.
Discussion
Our study on CXCL12, CXCR4 and the progression of
ESCC has three significant findings. First, we demon-
strate that a positive CXCL12 expression correlates sig-
nificantly with a lower RFS rate in our patient
population with ESCC. However, no significant correl-
ation was detected between CXCL12 or CXCR4 expres-
sion levels and any clinicopathological factors, such as
T/N stage, vessel or lymphatic invasion. These results
suggest that CXCL12 expression in ESCC promotes the
proliferation of the tumor and has a direct impact on
the recurrence rate, independent of invasion or metasta-
sis. The higher MIB-1 proliferation index with positive
CXCL12 expression strongly supports this hypothesis.
The multivariate analysis shows that positive CXCL12
expression is the only independent risk factor for
postoperative recurrence with a hazard ratio of 5.12, su-
perior to any of the other clinicopathological features.
CXCL12 may be a very useful biomarker for predicting
the outcome in ESCC patients, and more importantly,
could be a critical diagnostic marker for selecting appro-
priate treatments. In contrast, CXCR4 expression was
related to a higher MIB-1 index, but was not signifi-
cantly correlated with RFS. This indicates that CXCL12
expression has a more prominent role in cellular prolif-
eration, whereas CXCR4 expression only contributes.
Second, we report for the first time that the prolifera-
tive abilities of ESCC overexpressing or exposed to
CXCL12 are significantly enhanced compared with wild-
type cells in vitro. The fact that both CXCL12 overex-
pression and CXCL12 exposure similarly promote prolif-
eration denotes that ESCC cells expressing CXCL12
secrete this factor. In addition, it also suggests that cellu-
lar proliferation is stimulated by the binding of CXCL12
to CXCR4 on the cell membrane. The selective CXCR4
blockade by AMD3100 inhibits proliferation regardless
of CXCL12 overexpression or exposure.
Third, AMD3100 inhibits the tumor growth of ESCC
expressing CXCL12 in vivo, which has not been previ-
ously reported. These results suggest the possibility for
autocrine growth in ESCC similar to other carcinomas.
p = 0.28 p = 0.07
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Recurrence free survivalOverall survival 
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CXCR4(-)CXCL12(+), n=21
CXCR4(-)CXCL12(-),
n=10
CXCR4(+)CXCL12(-), 
n=7
CXCR4(-)CXCL12(+), n=21 CXCR4(+)CXCL12(+), n=41
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Fig. 4 Survival curves of patients after esophagectomy among the four groups. No significant difference was observed; however, CXCL12-positive
ESCC tended to be associated with a poor prognosis regardless of the positive or negative expression of CXCR4
Table 4 Univariate and multivariate analyses to determine the
risk factor for ESCC recurrence
Recurrence-free survival
Univariate Multivariate
Characteristic p value HR (95 % CI) p value
Positive CXCL12 expression (+/−) 0.021 5.12 (1.54–17.01) 0.008
Positive CXCR4 expression (+/−) 0.97
pT (≥pT3 vs < pT3) 0.10
Lymph node metastasis (+/−) 0.005
Lymphatic invasion (+/−) 0.002 1.84 (1.24–2.72) 0.002
Vessel invasion (+/−) 0.004 2.13 (1.03–4.39) 0.04
HR hazard ratio, CI confidence interval
Table 5 MIB-1index with or without CXCR4 or CXCL12
expression
CXCR4 negative CXCR4 positive
CXCL12 negative 9.6 % (0–58.1 %) 7.2 % (0–52.5 %)
n = 10 n = 7
CXCL12 positive 7.2 % (0–51.1 %) 24.1 % (0–68.2 %)
n = 21 n = 41
All percentage values are median (range)
p = 0.12
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Barbieri et al. reported that the overexpression of
CXCL12 and CXCR4 induces autocrine and paracrine
cellular proliferation in human pituitary adenomas [14].
Moreover, Uchida et al. reported the involvement of an
autocrine CXCL12/CXCR4 system on the distant metas-
tasis of human oral squamous cell carcinoma [15]. It is
possible that ESCC has an autocrine growth system;
however, further studies are required to prove this.
Taken together, CXCL12 is not only a promising bio-
marker but also a molecular target for inhibiting
proliferation. Using CXCL12 as a marker of poor prog-
nosis, patients with CXCL12-positive ESCC are at a high
risk of recurrence. Therefore, adjuvant or neo-adjuvant
therapy might be indicated to avoid recurrence after an
esophagectomy. In terms of molecular therapy, our
study denotes the possibility of a cell proliferation block-
ade through the CXCL12/CXCR4 signalling axis. Our
findings provide further evidence for the mechanism of
CXCL12/CXCR4-mediated cellular proliferation, leading
to novel therapeutic strategies to prevent tumor progres-
sion that may bring CXCL12/CXCR4-targeted therapy
closer to clinical reality.
However, our immunohistochemical analyses demon-
strated that patients with positive CXCL12 expression,
including both CXCR4 positive and negative patients,
have a poorer prognosis. This result indicates the possi-
bility of additional mechanisms (other than binding to
CXCR4 and an enhancement of proliferation) by which
CXCL12 promotes ESCC development. Several studies
have reported the relationship between CXCL12 and in-
vasion of malignant tumors other than ESCC [18–22].
Kryczek et al. reported that CXCL12 and vascular endo-
thelial growth factor synergistically induce neoangiogen-
esis in human ovarian cancers [23]. Further studies are
necessary to investigate the influence of CXCL12 on
tumor cell mortality in the context of ESCC.
Several studies by other groups have demonstrated
that the expression of CXCR4 or CXCL12 in cancer cells
worsens the prognosis in patients with ESCC. Goto et al.
showed that CXCR4 expression is associated with a poor
prognosis in patients with ESCC [24], while Sasaki et al.
showed that CXCL12 and its receptor CXCR4 correlated
with nodal metastasis in submucosal ESCC [25]. Sasaki
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Fig. 5 Quantitative real-time RT-PCR (evaluation of CXCL12 expression). a The CXCL12 mRNA expression level varies according to the cell lines.
b The TE4CXCL12+ cell line overexpresses CXCL12 410-fold higher than the control TE4 cell line
Fig. 6 In vitro proliferation assay; TE4 with exposure to CXCL12 and/
or AMD3100. TE4 cells exposed to CXCL12 exhibited a significantly
higher proliferation index than untreated TE4 cells (p = 0.002), and
TE4 cells exposed to AMD3100 showed a significantly lower
proliferation index than untreated TE4 cells (p = 0.001). CXCL12 did
not increase the proliferation rate of TE4 cells exposed to AMD3100
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et al. further reported that positive CXCL12 expression
was associated with poor prognosis in patients with
ESCC; however, similar to our results, positive CXCR4
expression was not [26]. We thought that this inconsist-
ency was likely caused by the differences in the back-
ground of patients. Further assessment regarding
CXCR4 expression in ESCC and its function is
necessary.
AMD3100 did not fully prevent the proliferation of
the TE4 and TE4CXCL12+ cell lines in our study, suggest-
ing that CXCL12 may promote the proliferation of
ESCC through other pathways in addition to CXCR4.
*: significant difference (p = 0.001, Mann–Whitney U test)
**: significant difference (p = 0.03, Mann–Whitney U test)
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Fig. 7 In vitro proliferation assay; TE4 and TE4CXCL12+ cells exposed or not to AMD3100. TE4CXCL12+ cells showed a significantly higher proliferation
index than wild type TE4 cells (p = 0.03). AMD3100 significantly decreases the proliferation of both TE4 and TE4CXCL12+ cells (both p = 0.001).
Overexpression of CXCL12 did not increase the proliferation of TE4 exposed to AMD3100
Fig. 8 In vivo proliferation assay; TE4CXCL12+ with or without infusion of AMD3100. TE4CXCL12+ mice continuously infused with AMD3100 showed
smaller tumors than control mice at all time points. AMD3100 significantly decreases the tumor size on day 14 (p = 0.03)
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For example, CXCR7, which is a novel receptor of
CXCL12, was reported to be involved in the progression
of several carcinomas [27–29]. However, we did not as-
sess the expression of CXCR7 in ESCC, and we cannot
discuss whether CXCL12-CXCR7 axis is related to the
proliferation of the ESCC cell line. Furthermore, our
IHC showed that CXCL12 positive expression was re-
lated to poor prognosis while CXCR4 positive expression
was not. It is possible that this result was caused by
CXCR7 involvement (i.e. CXCL12 promotes ESCC pro-
gression through not only CXCR4 but also CXCR7, and
causes poorer RFS).
Although CXCL12 promoted the proliferation index in
vitro, and AMD3100 suppressed the proliferation index
in vitro, as well as the tumor size in vivo, our study did
not disclose whether the CXCL12/CXCR4 axis is re-
sponsible for ESCC survival or apoptosis. Zhou et al. re-
ported that CXCR4 mediates survival of glioma cells
through Akt pathway [30]. Moreover, Liao et al. reported
that AMD3100 reduces CXCR4-mediated survival and
metastasis of osteosarcoma by inhibiting JNK and Akt,
but not p38 or Erk1/2, pathways [31]. To assess whether
CXCL12/CXCR4 is involved in survival or apoptosis of
ESCC, further studies are needed, including an examin-
ation of signal transduction following CXCL12-CXCR4
binding.
This study has three other limitations. First, we only
surveyed CXCL12 and CXCR4 expression of resected
ESCC without preoperative therapy. We cannot con-
clude that CXCL12 expression is a biomarker of progno-
sis regardless of chemotherapy or radiation therapy prior
to surgery. Second, we used one ESCC cell line, TE4, for
in vitro and in vivo studies. TE4 and its transfectant
demonstrated that CXCL12 increases cell proliferation;
however, we did not test the other cell lines to exclude a
cell line specific relationship. Third, we did not evaluate
the downstream targets following CXCL12 stimulation.
Several studies have reported the involvement of signal
transduction, such as the ERK1/2 or Akt pathways in
the proliferation of cancers [6, 14]. Therefore, further
studies are required to assess the signal transduction
after CXCL12-CXCR4 binding in ESCC.
Despite these limitations, our study demonstrates the
potential for CXCL12 to become a useful marker for
predicting the outcome in patients with ESCC and the
development a new therapeutic target molecule to sup-
press ESCC progression.
Conclusions
In this study, we demonstrated that the expression of
CXCL12 in ESCC is an independent risk factor of recur-
rence after surgery through immunohistochemistry and
we showed that CXCL12 promotes ESCC proliferation.
Blocking the binding of CXCL12 to CXCR4 decreases
ESCC growth both in vitro and in vivo. Therefore,
CXCL12 has the potential to become a biomarker for
prognosis prediction and a therapeutic target in patients
with ESCC.
Abbreviations
CXCL12, CXC-chemokine ligand 12; CXCR4, CXC-chemokine receptor 4; ESCC,
esophageal squamous cell carcinoma
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